With or without short covering, if DDD stops making loss this or next quarter (they should be able to do that by consolidating some facilities, which they are actually doing at present), and if it continues to grow its healthcare sector at present rate (most likely at even higher rate), I guess the share price would be at least $15 to $20 by this time next year.
This company is currently all about management. Their products are good and competative. With 48% gross margin, they should easily be able to generate net income. Their OpEx is too high at the moment. Let's hope the next CEO will do a better job.
DDD Healthcare is growing excellently with $99 million revenue for the 9 months ended last quarter.
DDD has announced today its Simbionix simulator is going to be used for hysterectomy operation training, it has already been used for heart and kidney surgery, etc. I could easily imagine DDD’s Simbionix simulator is going to be used for all operation training in the future.
I have just bought some more DDD shares for the long term holding.